(UroToday.com) She first reviewed the results of EV-301 (Abstract 393) which provided level 1 evidence of overall survival benefit with EV compared to single-agent chemotherapy in patients who progressed on platinum chemotherapy and immune checkpoint blockade. The trial schema and relevant overall survival data are re-shown below. EV also demonstrated a progression-free survival benefit and improved overall response rates to 41% from 18% with single-agent chemotherapy.